Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AnaptysBio, Inc. filings document the company’s transition to a royalty management business and its Nasdaq-listed common stock under the symbol ANAB. Recent Form 8-K and 8-K/A filings cover the completed separation of First Tracks Biotherapeutics, related separation and transition services agreements, pro forma financial information, and material-event reporting tied to the new corporate structure.
The filing record also includes disclosures on operating and financial results, Regulation FD materials, stock repurchase authorizations, governance matters, and contract litigation involving the Jemperli Collaboration and Exclusive License Agreement. These documents frame AnaptysBio’s capital structure, collaboration rights, royalty-related business focus, and public-company reporting obligations.
AnaptysBio plans to separate its biopharma operations into a new public company, First Tracks Biotherapeutics, in Q2 2026, while the existing company will focus on managing royalty streams from Jemperli with GSK and imsidolimab with Vanda. A Form 10 for the spin-off has been filed, and leadership and board line-ups for First Tracks are outlined.
For Q4 2025, collaboration revenue rose to $108.2 million and AnaptysBio generated net income of $49.6 million, versus a loss a year earlier, driven largely by Jemperli milestones and higher royalties. For 2025, collaboration revenue reached $234.6 million, with a narrowed net loss of $13.2 million. Cash, cash equivalents and investments were $311.6 million as of December 31, 2025, after repurchasing 3.44 million shares under a $175 million program.
LOUMEAU ERIC J reported multiple insider transaction types in a Form 4 filing for ANAB. The filing lists transactions totaling 30,000 shares at a weighted average price of $41.85 per share. Following the reported transactions, holdings were 35,000 shares.
AnaptysBio insider Eric J. Loumeau has filed a Form 144 to sell 10,000 shares of the company’s common stock. The shares are to be sold through Morgan Stanley Smith Barney on NASDAQ, with an indicated aggregate market value of 540000.00, and are part of a class with 27,688,470 shares outstanding.
The 10,000 shares were acquired on 02/11/2026 via a stock option exercise from the issuer, paid in cash on the same date. The filing also lists multiple prior open-market sales of AnaptysBio common stock by Loumeau over the past three months, including 10,000-share blocks sold on 12/17/2025 and 12/22/2025 for gross proceeds of 460000.00 and 510000.00, respectively.
Morgan Stanley filed an amended Schedule 13G reporting its beneficial ownership in AnaptysBio, Inc. common stock has fallen below 5% of the class. Morgan Stanley reports beneficial ownership of 1,006,063 shares, representing 3.6% of AnaptysBio’s common stock.
Morgan Stanley Capital Services LLC separately reports beneficial ownership of 879,351 shares, or 3.2% of the class, and also notes it is no longer a beneficial owner of more than five percent. The filing states the securities were acquired and are held in the ordinary course of business, not to change or influence control of AnaptysBio.
AnaptysBio, Inc. received an updated ownership report from Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, who collectively report beneficial ownership of 813,571 shares of AnaptysBio common stock, representing 2.9% of the outstanding class as of the reported date. The reporting persons disclose shared voting and shared dispositive power over these shares, with no sole voting or dispositive authority.
They state that they now hold 5 percent or less of AnaptysBio’s common stock and certify that the securities were not acquired and are not held for the purpose of changing or influencing control of the company, but instead on a passive basis.
AnaptysBio director Magda Marquet reported an option exercise and related share sales. On January 15, 2026, she exercised a fully vested stock option for 11,000 shares of common stock at an exercise price of $26.11 per share, increasing her direct holdings to 20,930 shares. That same day, she sold 9,290 shares of common stock at a weighted average price of $48.1162 per share, in multiple trades between $47.595 and $48.54, and an additional 1,710 shares at a weighted average price of $48.849 per share, in trades between $48.625 and $48.88. After these transactions, she directly owned 9,930 shares of common stock and held additional options to purchase up to 70,104 shares of common stock that vest according to their terms.
A security holder has filed to sell 11,000 shares of common stock. The shares are expected to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ exchange around 01/15/2026, with an aggregate market value of $530,531.10 based on the filing.
The 11,000 shares to be sold were acquired on 01/15/2026 through a stock option exercise paid in cash. Shares of the issuer outstanding were 27,688,470, which provides a baseline for the size of this planned sale.
AnaptysBio Chief Medical Officer Paul F. Lizzul reported routine equity activity. On January 7, 2026, 8,525 restricted stock units (RSUs) converted into the same number of common shares for no cash cost, reflecting scheduled vesting. The RSU award is set to vest 25% per year starting January 7, 2026, as long as he continues providing services.
On January 8, 2026, he sold 3,650 shares of AnaptysBio common stock at $44.71 per share. The footnotes state this was a “sell to cover” transaction to satisfy tax withholding obligations tied to the RSU vesting, and was not a discretionary sale. After these transactions, he directly held 42,088 shares of common stock and 25,575 RSUs.
This notice under Rule 144 reports that insider Paul F. Lizzul intends to sell 3,650 shares of common stock of the issuer through Morgan Stanley Smith Barney LLC on or around 01/08/2026 on the NASDAQ exchange. The shares come from restricted stock units acquired from the issuer on 01/08/2026, with the purchase price paid in cash.
Over the prior three months, the same seller reported additional sales of the issuer’s common stock: 2,235 shares on 01/07/2026 for gross proceeds of $98,138.85, 4,219 shares on 01/05/2026 for $189,644.05, and 1,500 shares on 12/22/2025 for $75,000. By signing the notice, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
AnaptysBio, Inc. reported insider equity activity by its Chief Financial Officer, Dennis Mulroy. On January 7, 2026, 6,700 restricted stock units (RSUs) were settled into an equal number of common shares for no cash consideration, increasing his directly held common stock to 24,367 shares. The RSU award vests in 25% increments annually starting January 7, 2026, subject to continued service.
On January 8, 2026, he sold 2,515 common shares at $44.71 per share to cover tax withholding obligations related to the RSU vesting, described as a non-discretionary “sell to cover” transaction. After these transactions, he directly held 21,852 common shares and 20,100 RSUs.